PMID: 2108908Mar 1, 1990Paper

Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia

Gut
N Hoogerbrugge-vd LindenM van Blankenstein

Abstract

Nine patients with heterozygous familial hypercholesterolaemia were treated for eight weeks with either 40 mg pravastatin or placebo under double blind conditions. Six patients received pravastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Treatment with pravastatin resulted in a significant decrease in plasma cholesterol caused by a decrease in low density lipoprotein cholesterol (LDL-c) of 30% (p less than 0.005). We determined the effect of this medication on the lithogenicity of bile. Cholesterol saturation index of fasting gall bladder bile decreased with 23% (p less than 0.01) from 1.06 to 0.75 during treatment with pravastatin. A reduction of 24% (p less than 0.01) in molar percentage of biliary cholesterol was seen. After treatment the total bile acid excretion in faeces and the molar percentage of biliary bile acids were not significantly changed, suggesting that pravastatin does not influence bile acid biosynthesis to a significant extent. These findings indicate that treatment with pravastatin can decrease the incidence and complications of cholesterol gall stones.

References

May 12, 1975·Analytical Biochemistry·T G RedgraveC E West
Sep 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W C DuaneR L Gebhard
Jan 1, 1985·Metabolism: Clinical and Experimental·O LeissJ Augustin
Dec 1, 1972·The Journal of Clinical Investigation·S M GrundyR D Adler
Jun 1, 1970·Clinica Chimica Acta; International Journal of Clinical Chemistry·A Bruusgaard
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S M Grundy, D W Bilheimer

❮ Previous
Next ❯

Citations

Mar 21, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T E MiettinenT A Miettinen
Jul 1, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G KallienJ Scheibner
Jan 1, 1992·European Journal of Clinical Pharmacology·H Vanhanen, T A Miettinen
Apr 23, 1992·Biochimica Et Biophysica Acta·R Coleman, K Rahman
Aug 3, 2002·European Journal of Clinical Investigation·C-G HillebrantC Einarsson
Jan 1, 1996·Scandinavian Journal of Gastroenterology. Supplement·J W SmitG P VanBerge-Henegouwen
Feb 4, 1999·Scandinavian Journal of Gastroenterology·T E Miettinen, M Vuoristo
Feb 12, 2009·Gastroenterology·Chung-Jyi TsaiEdward L Giovannucci
Feb 20, 2013·European Journal of Clinical Investigation·Helen H WangDavid Q-H Wang
Apr 18, 2016·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu
Jun 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J W SmitG P Vanberge-Henegouwen
Apr 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P LoriaN Carulli
Jun 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G MazzellaE Roda
Apr 1, 1991·DICP : the Annals of Pharmacotherapy·R H Raasch
Jul 2, 2003·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·L Rodríguez-PáezC Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.